Swiss pharmaceutical company, Novartis Pharma AG, shared new data from the SMART study reinforcing the clinical advantages of its single-dose gene therapy, Zolgensma, in treating Spinal Muscular Atrophy (SMA). This trial broadens the existing evidence base for Zolgensma's use among a heavier and older demographic, specifically children aged between 1.5 and 9.1 years.
The findings reveal that nearly all of the children treated were able to maintain or even enhance their motor function after 52 weeks. Furthermore, most of the patients transitioned from other long-term administered treatment regimes to Zolgensma.
SMA, an uncommon, genetic neuromuscular disease, is primarily known as the leading genetic cause of infant death. This detrimental condition is triggered by the absence of an active SMN1 gene. SMA's severest forms lead to a quick, irreversible loss of motor neurons, impacting core muscular activities like breathing, swallowing, and basic movement.
As it stands, Zolgensma is the only approved gene therapy designed to directly treat the genetic cause of SMA. It substitutes the function of the flawed or absent SMN1 gene, preventing the disease's progression through maintaining the SMN protein's expression with a single IV infusion.
The SMART study stands as the inaugural open-label clinical trial involving Zolgensma that includes previously treated patients.
According to Novartis, the SMART study's final data underscore Zolgensma's safety and effectiveness in treating children with SMA aged approximately 18 months to 9 years. Almost all the patients were able to sustain or even boost their motor function from the baseline at the time of the analysis's conclusion. Interestingly, at the end of the 52nd week, almost all patients who could sit slightly without any support continued to meet this milestone.
Currently, Zolgensma is approved in over 51 countries globally, and has been administered to more than 3,700 patients in clinical trials, managed access programs, and commercial settings.
Additionally, Novartis holds an exclusive, worldwide license with Nationwide Children's Hospital for the intravenous and intrathecal delivery of the AAV9 gene therapy, used to treat all types of SMA.
